Table 3.
Clinicopathological features of 12 skip N2 patients
| Pt. no. | Age/sex | Side | Location (lobe) | Histology | Tumor size (mm) | Proportion of GGO (%) | Distance to pleura (mm) | SLX (U/mL) | ly | v | pPL | Site of skip N2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 |
73/M |
Rt |
Upper |
Sq |
15 |
19 |
4 |
36.2 |
+ |
- |
0 |
No. 2R, 4R LN |
| 2 |
34/F |
Rt |
Upper |
Ad |
16 |
68 |
13 |
27.4 |
+ |
- |
0 |
No.4R LN |
| 3 |
70/F |
Rt |
Upper |
Ad |
21 |
47 |
30 |
21.4 |
+ |
+ |
0 |
No.2R, 4R LN |
| 4 |
62/F |
Rt |
Upper |
Ad |
14 |
24 |
28 |
13.1 |
+ |
- |
0 |
No. 4R LN |
| 5 |
71/M |
Rt |
Lower |
Ad |
30 |
9 |
0 |
40.2 |
- |
- |
0 |
No. 7 LN |
| 6 |
61/F |
Rt |
Lower |
Ad |
24 |
27 |
0 |
32.8 |
+ |
+ |
1 |
No. 7 LN |
| 7 |
60 M |
Rt |
Lower |
Ad |
24 |
23 |
0 |
29.0 |
+ |
+ |
0 |
No.2R, 4R LN |
| 8 |
62/F |
Lt |
Upper |
Ad |
20 |
72 |
5 |
23.6 |
+ |
+ |
1 |
No. 5 LN |
| 9 |
81/M |
Lt |
Upper |
Sq |
27 |
13 |
0 |
24.5 |
+ |
- |
2 |
No. 5 LN |
| 10 |
63/M |
Lt |
Lower |
Ad |
15 |
38 |
0 |
28.0 |
+ |
- |
0 |
No. 5 LN |
| 11 |
60/M |
Lt |
Lower |
Ad |
23 |
7 |
14 |
27.0 |
- |
+ |
0 |
No. 7 LN |
| 12 | 57/F | Lt | Lower | Ad | 20 | 3 | 0 | 33.0 | + | - | 0 | No. 5 LN |
Pt. no., patient number; M,male; F, female; Rt, right; Lt, left; Ad, adenocarcinoma; Sq, squamous cell carcinoma; GGO, ground-glass opacity; distance to pleura, measured on computed-tomography; SLX, sialyl Lewis X; ly, lymph vessel invasion factor; v, venous invasion factor; pPL, pathological pleural invasion factor; No. 2R, upper paratracheal lymph node; No. 4R LN, lower paratracheal lymph node; No. 5 LN, subaortic lymph node; No. 7 LN, subcarinal lymph node.